AFMD News and Press, Affimed N.V. From 11/10/21

Image source: The Motley Fool. Affimed NV (NASDAQ: AFMD) Q3 2021 Earnings Call Nov 10, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Affimed NV (AFMD) Q3 2021 Earnings Call Transcript

Affimed N.V. (AFMD) Q3 2021 Earnings Conference Call November 9, 2021, 8:30 AM ET Company Participants Adi Hoess – Chief Executive Officer Alex Fudukidis – Head of Investor Relations Andreas Harstrick – Chief Medical Officer Arndt Schottelius – Chief Scientific Off...

Affimed (AFMD -10.3%) has lost about a tenth of its value to reach near a three-month low after the company filed a mixed securities shelf offering valued at $100M on Wednesday. The filing follows the Q3 results reported by the German biotech for 2021. Q3 results for the compan...

Affimed (NASDAQ:AFMD): Q3 GAAP EPS of  €0.14. Revenue of €8.7M. Shares +1.1% PM. Press Release For further details see: Affimed reports Q3 results

AFM13 monotherapy: Enrollment is on track and expected to be completed in the first half of 2022. AFM13 combination with NK cells: Updated data to be presented at company-sponsored event in mid-December 2021. AFM24 monotherapy: Identified recommended Phase 2 dose (480 mg weekly); ...

Affimed (NASDAQ:AFMD) has begun patient recruitment for a proof of concept trial of AFM24 in combination with NKGen Biotech's SNK01. AFM 24 is a epidermal growth factor receptor ("EGFR")  and CD16A-binding innate cell engager, while SNK01 is an autologous NK cell therapy made from a pati...

Patient recruitment is open for the first-in-human proof of concept trial of the combination of AFM24 and SNK01 NK cells in three advanced or metastatic EGFR-expressing cancers, namely non-small cell lung cancer, squamous cell carcinoma of the head and neck and colorectal cancer ...

Derived from Affimed’s ROCK ® platform, AFM28 binds selectively and with high affinity the surface antigens CD123 and CD16A AFM28 shows better killing of primary leukemic blasts in comparison to monoclonal antibodies which may lead to enhanced ADCC in patients ...

A poster presentation featuring preclinical data on AFM28, a novel Innate Cell Engager developed for treatment of Acute Myeloid Leukemia and other CD123+ myeloid malignancies A poster presentation on AFM13 precomplexed NK cells that maintained biological activity and potency a...

HEIDELBERG, Germany, Oct. 29, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that it will release third quarter 2021 results on Wednesday, November 10, 202...